The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
MGC Pharmaceuticals has received permission to import psilocybin into Slovenia.
PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
In a partnership that has been described as “an important step to reintroduce psychedelics into society”, Dimensions and the New Health Club are joining together to...
Regulatory approvals for psychedelic medicines are becoming a reality, and the focus in policy and advocacy work is shifting from “if” to “when” and – most...
With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
The Dutch Parliament has established an independent State Commission to research the legal status of MDMA and provide advice on its medical use.
